A Director at KalVista Pharmaceuticals Inc (NASDAQ: KALV) is Buying Shares

By Carrie Williams

Today, a Director at KalVista Pharmaceuticals Inc (KALVResearch Report), Albert Cha, bought shares of KALV for $1.09M.

Following this transaction Albert Cha’s holding in the company was increased by 14.46% to a total of $24.93 million. Following Albert Cha’s last KALV Buy transaction on September 12, 2018, the stock climbed by 1.4%.

See today’s analyst top recommended stocks >>

Currently, KalVista Pharmaceuticals Inc has an average volume of 182.7K.

Starting in July 2018, KALV received 14 Buy ratings in a row.

The insider sentiment on KalVista Pharmaceuticals Inc has been negative according to 26 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.

Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: hereditary angioedema (HAE) and diabetic macular edema (DME).